Article

Personalized medicine in the genomic age of breast cancer

Author(s):

Debu Tripathy

We're not going to find one drug to treat everyone. That's why molecular medicine, or personalized medicine, has become so important in treating breast cancer, in fact - all cancers. And like all cancers, there will not be a one-size fits all treatment. Watch Dr. Tripathy's latest video blog to learn more:

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Related Content
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis: © stock.adobe.com.
June 16th 2025

FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis

Spencer Feldman
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Sara Gideon, nurse practitioner, is a compassionate oncology nurse who supports patients with cancer: © stock.adobe.com.
June 15th 2025

Where Compassion Meets Care in Breast Cancer

Margaret Valenti, DNP, RN, AHN-BC, MEDSURG-BC
Sara Gideon, nurse practitioner, is a compassionate oncology nurse who supports patients with cancer, streamlines care and leads with dedication.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of hands.
June 14th 2025

My Oncology Nurse Knows Me so Well

Kellie Defelice
Patricia Chin, a registered nurse, forms meaningful bonds with patients, providing expert care, emotional support and kindness through cancer treatment.
Image of debbie.
June 13th 2025

Survivorship, the Hardest Part After Cancer?

Debbie Legault
Survivorship after cancer can be harder than treatment. My daughter faces lasting side effects, fear, and uncertainty while building a life she hopes to live fully.